Life Stem Genetics Inc. (LIFS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Life Stem Genetics Inc. (LIFS) trades at $0.0001. Life Stem Genetics Inc. is a development-stage biotechnology company focused on establishing a global network of stem cell therapy clinics. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for LIFS: LIFS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LIFS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on LIFS.
How is this calculated? →Life Stem Genetics Inc. (LIFS) Healthcare & Pipeline Overview
Life Stem Genetics Inc. is a development-stage biotechnology company establishing a global network of stem cell therapy clinics. It offers diverse treatments for degenerative conditions, cancer, and anti-aging, alongside nutraceuticals and stem cell banking, supported by a collaboration with American CryoStem Corporation.
What Is the Investment Thesis for LIFS?
Life Stem Genetics Inc. presents an investment profile centered on its early-stage development within the burgeoning biotechnology sector, specifically regenerative medicine. The company's strategic focus on establishing a global network of stem cell therapy clinics, coupled with a diverse offering of treatments, nutraceuticals, and stem cell banking, positions it to potentially capitalize on the growing interest in advanced medical therapies. Value drivers include the increasing acceptance and research into stem cell applications for a wide range of conditions, from degenerative diseases to anti-aging. The strategic collaboration with American CryoStem Corporation could provide a competitive advantage through shared expertise or resources. However, as a development-stage company, LIFS faces inherent risks associated with early-stage biotech ventures, including the need for substantial capital, potential regulatory hurdles for novel therapies, and the challenges of scaling a global clinic network. Its listing on the OTC Other tier also introduces risks related to limited regulatory oversight and potentially lower liquidity. Future growth catalysts would involve successful clinical advancements, expansion of its clinic footprint, and positive market reception of its therapeutic solutions.
Based on FMP financials and quantitative analysis
LIFS Key Highlights
Market Capitalization: $0.00 billion, reflecting its early-stage development and OTC listing status.
- Dividend Yield: None, consistent with a development-stage company reinvesting any available capital into growth initiatives.
- Strategic Collaboration: Ongoing agreement with American CryoStem Corporation, potentially enhancing its operational capabilities in stem cell services.
- Business Model: Focused on establishing a global network of stem cell therapy clinics, alongside offering nutraceuticals, medical supplements, and stem cell banking services.
- Therapeutic Scope: Provides a broad range of stem cell treatments targeting degenerative conditions, cancer, weight management, anti-aging, and anti-viral applications.
Who Are LIFS's Competitors?
LIFS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LIFS's Key Strengths?
Specialized focus on a broad range of stem cell therapies for diverse conditions.
- Comprehensive offering including clinics, nutraceuticals, and stem cell banking.
- Strategic collaborative agreement with American CryoStem Corporation.
- Operating in the high-growth regenerative medicine sector.
What Are LIFS's Weaknesses?
Currently in development phase, indicating limited operational history and revenue.
- Listed on the OTC Other tier, implying limited regulatory oversight and potential liquidity issues.
- High-risk nature inherent to early-stage biotechnology ventures.
- "Unknown" disclosure status, posing transparency challenges for investors.
What Could Drive LIFS Stock Higher?
LIFS catalyst: Successful establishment and opening of initial stem cell therapy clinics, demonstrating tangible progress in its global network strategy.
- Announcement of new clinical trials or significant advancements in its existing stem cell treatment protocols, potentially leading to expanded therapeutic applications.
- Release of detailed financial disclosures or operational updates, which could improve transparency and investor confidence.
- Continued development and expansion of its nutraceuticals, medical supplements, and stem cell banking services, diversifying revenue streams.
What Are the Key Risks for LIFS?
Financial-distress signal — its Altman Z-Score of -1.68 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- High-risk nature of early-stage biotechnology ventures, including significant capital requirements and uncertain timelines for product development and market penetration.
- Regulatory hurdles and potential for stringent oversight in the stem cell therapy market, which could delay or prevent commercialization of treatments.
- Limited public disclosure and OTC Other listing, contributing to low liquidity, high volatility, and difficulty in assessing the company's true financial and operational status.
- Intense competition from more established biotechnology firms and research institutions with greater resources and clinical trial experience.
- Challenges in scaling a global network of clinics, including securing necessary licenses, qualified personnel, and patient adoption across different regions.
What Are the Growth Opportunities for LIFS?
- Expansion of Global Clinic Network: Life Stem Genetics Inc.'s primary growth driver involves establishing and expanding its global network of specialized stem cell therapy clinics. This strategy aims to increase geographical reach and patient access to its diverse range of treatments, including Adistem therapies for orthopedic, neurological, and lung diseases. The global regenerative medicine market, which includes stem cell therapies, is projected to grow significantly, with estimates often placing its value in the tens of billions of dollars by the end of the decade. By strategically expanding its physical presence, LIFS can capture a larger share of this growing market, particularly in regions with high demand for advanced regenerative treatments.
- Development and Commercialization of New Therapies: As a biotechnology company, LIFS has the opportunity to develop and introduce novel stem cell treatments and protocols. This could include refining existing therapies for degenerative conditions, cancer, and anti-aging, or exploring new applications based on ongoing research. The continuous innovation in stem cell science allows for the potential to address unmet medical needs and expand its therapeutic portfolio. Successful development and regulatory approval of new, highly effective treatments could significantly enhance the company's market position and revenue streams, attracting a broader patient base seeking cutting-edge medical solutions.
- Growth in Nutraceuticals and Medical Supplements: Beyond clinical services, Life Stem Genetics Inc. offers a suite of nutraceuticals, medical supplements, and intravenous nutritional cocktails. This segment represents a substantial growth opportunity, leveraging the increasing consumer interest in wellness, preventative health, and complementary therapies. The global nutraceuticals market is a multi-billion dollar industry, with consistent growth driven by health-conscious consumers. By integrating these products with its stem cell therapies, LIFS can create a holistic health offering, potentially increasing customer loyalty and generating recurring revenue streams from product sales that support and enhance the outcomes of its primary treatments.
- Expansion of Stem Cell Banking Services: The company's stem cell banking services offer a long-term growth avenue. As awareness of the potential future therapeutic uses of autologous (self-donated) stem cells grows, demand for cryopreservation services is expected to rise. This market is driven by individuals seeking to safeguard their health for potential future medical needs, including regenerative treatments for various diseases. By expanding its banking capacity and outreach, LIFS can tap into this growing market, providing a valuable service that complements its clinical offerings and establishes a recurring revenue model through storage fees, while also potentially creating a pipeline of future therapy recipients.
- Leveraging Strategic Collaborations: The ongoing strategic collaborative agreement with American CryoStem Corporation presents a significant opportunity for Life Stem Genetics Inc. Such partnerships can facilitate shared research, development, and commercialization efforts, potentially accelerating the introduction of new therapies or expanding market reach. Collaborations can provide access to specialized technologies, intellectual property, or manufacturing capabilities that would be costly or time-consuming to develop internally. By effectively leveraging this partnership, LIFS could enhance its operational efficiency, strengthen its scientific credibility, and gain a competitive edge in the complex and capital-intensive stem cell therapy market, driving innovation and market penetration.
What Threats Does LIFS Face?
- Intense competition from established biotech and pharmaceutical companies.
- Significant regulatory hurdles and potential for adverse policy changes in regenerative medicine.
- Challenges in securing adequate funding for R&D and global expansion.
- Clinical trial failures or limited efficacy outcomes for therapies.
What Are LIFS's Competitive Advantages?
- Specialized Therapeutic Focus: Concentration on a broad range of stem cell therapies, including Adistem treatments, for specific and complex conditions like orthopedic, neurological, and lung diseases, creates a niche expertise.
- Comprehensive Service Offering: Integration of clinical treatments, nutraceuticals, and stem cell banking provides a holistic approach to health and regenerative medicine, potentially increasing patient engagement and loyalty.
- Strategic Collaboration: The agreement with American CryoStem Corporation may offer access to proprietary technologies, research, or operational efficiencies, providing a competitive edge in the highly specialized field of cryopreservation and stem cell application.
- Early-Mover Advantage in Clinic Network: While in development, the stated goal of establishing a global network of specialized clinics could position LIFS to capture market share in regions where advanced stem cell therapies are in high demand but clinic access is limited.
What Does LIFS Do?
Life Stem Genetics Inc., founded in 2012 and headquartered in Beverly Hills, California, is a biotechnology enterprise currently in its development phase. The company's core strategic objective is to establish a global network of specialized clinics dedicated to advanced stem cell therapy. Its comprehensive portfolio extends beyond clinical treatments to include a range of nutraceuticals, medical supplements, and intravenous nutritional cocktails designed to support overall health and regenerative processes. A significant component of its service offering is stem cell banking, providing individuals with the opportunity to preserve their own stem cells for potential future therapeutic use. Life Stem Genetics Inc. offers a variety of stem cell treatments targeting a broad spectrum of health concerns, including degenerative conditions, various forms of cancer, and weight management programs. Additionally, the company provides anti-aging and anti-viral therapies, leveraging the regenerative potential of stem cells. A key aspect of its therapeutic approach involves Adistem stem cell treatments, specifically tailored for orthopedic, neurological, and lung diseases. Complementing these stem cell therapies, Life Stem Genetics Inc. also offers hyperbaric oxygen therapy, a treatment known for its potential to enhance healing and recovery. The company maintains a strategic collaborative agreement with American CryoStem Corporation, which could provide access to specialized technologies or expertise in the cryopreservation and application of stem cells, further solidifying its position in the evolving regenerative medicine landscape. Operating from East Stroudsburg, US, the company is focused on advancing its clinic network and therapeutic offerings.
What Products and Services Does LIFS Offer?
- Establishes and operates a global network of specialized stem cell therapy clinics.
- Provides a variety of stem cell treatments for degenerative conditions, cancer, and weight management.
- Offers anti-aging and anti-viral stem cell therapies.
- Delivers Adistem stem cell treatments specifically for orthopedic, neurological, and lung diseases.
- Provides hyperbaric oxygen therapy as a complementary treatment.
- Sells nutraceuticals, medical supplements, and intravenous nutritional cocktails.
- Offers stem cell banking services for cryopreservation and future therapeutic use.
- Maintains a strategic collaborative agreement with American CryoStem Corporation.
How Does LIFS Make Money?
- Generates revenue from fees for stem cell therapy treatments and related medical services provided at its clinics.
- Earns income from the sale of nutraceuticals, medical supplements, and intravenous nutritional cocktails.
- Receives fees for stem cell banking services, including initial processing and ongoing storage.
- Potentially benefits from collaborative agreements, which may involve shared intellectual property or revenue streams.
What Industry Does LIFS Operate In?
Life Stem Genetics Inc. operates within the dynamic and rapidly evolving biotechnology sector, specifically targeting the regenerative medicine and stem cell therapy market. This industry is characterized by significant scientific innovation, high research and development costs, and stringent regulatory pathways. The global stem cell therapy market is projected to experience substantial growth, driven by increasing prevalence of chronic diseases, advancements in stem cell research, and rising demand for personalized medicine. LIFS's strategy of establishing a network of clinics and offering a diverse suite of related products positions it to address various segments of this market, from direct patient care to preventative health and cell banking. The competitive landscape includes established pharmaceutical companies, specialized biotech firms, and academic institutions, all vying for market share in therapeutic development and clinical application. As a development-stage company, LIFS aims to carve out its niche by focusing on comprehensive service offerings and strategic partnerships, such as its collaboration with American CryoStem Corporation, to differentiate itself in a crowded and capital-intensive industry.
Who Are LIFS's Key Customers?
- Patients seeking treatment for degenerative conditions, including orthopedic, neurological, and lung diseases.
- Individuals undergoing cancer treatment or seeking complementary therapies.
- Clients interested in anti-aging and anti-viral therapies.
- Individuals seeking weight management solutions through stem cell applications.
- Health-conscious consumers purchasing nutraceuticals, medical supplements, and nutritional cocktails.
- Individuals and families opting for long-term stem cell banking services.
Company Profile
Life Stem Genetics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in East Stroudsburg, US. The company is led by CEO Gloria Simov. LIFS has traded publicly since 2013.
Key Financial Metrics
Return on equity for Life Stem Genetics Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -42.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Life Stem Genetics Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.68 places it in the distress zone, a signal of elevated financial risk.
LIFS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on a broad range of stem cell therapies for diverse conditions.
- Comprehensive offering including clinics, nutraceuticals, and stem cell banking.
- Strategic collaborative agreement with American CryoStem Corporation.
- Operating in the high-growth regenerative medicine sector.
Bear Case
- Currently in development phase, indicating limited operational history and revenue.
- Listed on the OTC Other tier, implying limited regulatory oversight and potential liquidity issues.
- High-risk nature inherent to early-stage biotechnology ventures.
- "Unknown" disclosure status, posing transparency challenges for investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
LIFS Latest News
No recent news available for LIFS.
LIFS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LIFS.
Price Targets
Wall Street price target analysis for LIFS.
LIFS MoonshotScore
What does this score mean?
The MoonshotScore rates LIFS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gloria Simov
Chief Executive Officer
Gloria Simov serves as the Chief Executive Officer of Life Stem Genetics Inc., guiding the company through its critical development phase within the biotechnology sector. While specific details of her prior career history and educational background are not provided, her leadership role at a company focused on establishing a global network of stem cell therapy clinics suggests a background in healthcare management, biotechnology, or a related scientific field. Her position involves overseeing the strategic direction, operational development, and collaborative initiatives crucial for a nascent enterprise in regenerative medicine.
Track Record: Under Gloria Simov's leadership, Life Stem Genetics Inc. has progressed in its stated mission to establish a global network of stem cell therapy clinics. A notable achievement includes the formation of a strategic collaborative agreement with American CryoStem Corporation, a key partnership for a company operating in specialized medical services. Her tenure is focused on laying the foundational elements for the company's future growth and market penetration in the stem cell therapy domain.
LIFS OTC Market Information
Life Stem Genetics Inc. trades on the OTC Other tier, which represents the lowest and most speculative category within the OTC Markets Group's three tiers (OTCQX, OTCQB, and OTC Other). Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and public disclosure, companies on the OTC Other tier have minimal to no reporting requirements. This tier typically includes shell companies, defunct entities, or companies with limited public information, making it a high-risk environment for investors due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited Public Information: "Unknown" disclosure status means investors lack critical financial and operational data for informed decisions.
- Minimal Regulatory Oversight: OTC Other companies are subject to significantly less scrutiny compared to major exchanges, increasing the risk of fraud or mismanagement.
- Low Liquidity and Volatility: Very low trading volume and wide bid-ask spreads can make shares difficult to trade, leading to potential significant price swings.
- Difficulty in Valuation: Lack of reliable financial reporting makes it extremely challenging to accurately value the company or its prospects.
- Potential for Penny Stock Fraud: OTC Other tier is often associated with "pump and dump" schemes due to low transparency and ease of manipulation.
- Verify any available financial statements, even if unaudited, for consistency and red flags.
- Research the background and track record of management beyond provided names.
- Investigate the legitimacy and operational status of its stated global clinic network.
- Confirm the specifics and current status of the collaborative agreement with American CryoStem Corporation.
- Scrutinize any public announcements or press releases for verifiable facts and progress.
- Assess the regulatory environment for its specific stem cell therapies and potential hurdles.
- Understand the company's funding status and capital requirements for its development phase.
- Established in 2012, indicating some operational longevity, albeit in a development phase.
- Stated focus on a specific, high-potential sector (stem cell therapy and regenerative medicine).
- Maintains a strategic collaborative agreement with American CryoStem Corporation, suggesting a verifiable external partnership.
- Identified CEO, Gloria Simov, provides a named individual responsible for leadership.
LIFS Healthcare Stock FAQ
What does Life Stem Genetics Inc. do?
Life Stem Genetics Inc. is a biotechnology company in its development phase, focused on establishing a global network of clinics specializing in stem cell therapy. Its core offerings include a variety of stem cell treatments addressing conditions such as degenerative diseases, cancer, weight management, anti-aging, and anti-viral applications.
What are the main risks for LIFS?
As an early-stage biotechnology company listed on the OTC Other tier, Life Stem Genetics Inc. faces several significant risks. These include the inherent high-risk nature of developing novel medical therapies, which requires substantial capital investment and carries uncertain timelines for clinical success and regulatory approval.
What revenue streams does Life Stem Genetics Inc. have in healthcare?
Life Stem Genetics Inc. aims to generate revenue through multiple streams within the healthcare sector, reflecting its diverse business model. The primary revenue source is expected to come from fees charged for its specialized stem cell therapy treatments, including Adistem treatments, administered at its developing network of clinics.
What are the key factors to evaluate for LIFS?
Evaluate LIFS on fundamentals, analyst consensus, and risk factors. Life Stem Genetics Inc. presents an investment profile centered on its early-stage development within the burgeoning biotechnology sector, specifically regenerative medicine. Not financial advice.
How frequently does LIFS data refresh on this page?
LIFS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LIFS's recent stock price performance?
Life Stem Genetics Inc. (LIFS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on a broad range of stem cell therapies for diverse conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LIFS overvalued or undervalued right now?
Life Stem Genetics Inc. (LIFS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LIFS before investing?
Before investing in Life Stem Genetics Inc. (LIFS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data. Details on CEO background, financial performance beyond market cap, and specific operational metrics are limited. The company is in a development phase, and its disclosure status is unknown, impacting the depth of analysis.